Education
About Us
Working with TipRanks
Follow Us
Arch Biopartners (TSE:ARCH)
:ARCH
ARCH Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.27 - C$2.20
Previous CloseN/A
Volume5.12K
Average Volume (3M)15.12K
Market Cap
C$121.93M
Enterprise ValueC$60.54M
Total Cash (Recent Filing)C$54.85K
Total Debt (Recent Filing)C$2.83M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding65,906,364
10 Day Avg. Volume23,204
30 Day Avg. Volume15,122
Financial Highlights & Ratios
PEG Ratio0.87
Price to Book (P/B)-20.01
Price to Sales (P/S)0.00
P/FCF Ratio-32.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
19.09% Insiders
―
Mutual Funds
― Other Institutional Investors
80.91% Public Companies and
Individual Investors
ARCH FAQ
What was Arch Biopartners’s price range in the past 12 months?
Arch Biopartners lowest stock price was C$1.27 and its highest was C$2.20 in the past 12 months.
What is Arch Biopartners’s market cap?
Arch Biopartners’s market cap is C$121.93M.
When is Arch Biopartners’s upcoming earnings report date?
Arch Biopartners’s upcoming earnings report date is Aug 27, 2025 which is in 70 days.
How were Arch Biopartners’s earnings last quarter?
Arch Biopartners released its earnings results on May 31, 2025. The company reported -C$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.009.
Is Arch Biopartners overvalued?
According to Wall Street analysts Arch Biopartners’s price is currently Overvalued.
Does Arch Biopartners pay dividends?
Arch Biopartners does not currently pay dividends.
What is Arch Biopartners’s EPS estimate?
Arch Biopartners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arch Biopartners have?
Arch Biopartners has 65,906,364 shares outstanding.
What happened to Arch Biopartners’s price movement after its last earnings report?
Arch Biopartners reported an EPS of -C$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.622%.
Which hedge fund is a major shareholder of Arch Biopartners?
Currently, no hedge funds are holding shares in TSE:ARCH
Arch Biopartners Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth C$60.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.46%
12-Months-Change
Fundamentals
Return on Equity
90.17%
Trailing 12-Months
Asset Growth
-69.28%
Trailing 12-Months
Company Description
Arch Biopartners
Arch Biopartners (ARCH) is a biotechnology company focused on developing innovative solutions for medical applications. The company is engaged in the research and development of novel therapeutics that target inflammation, organ injury, and bacterial infections. Arch Biopartners is particularly known for its lead drug candidate, Metablok, which is aimed at treating complications arising from inflammation and organ injury in conditions such as sepsis, COVID-19, and other critical care indications.
Technical Analysis
Oncolytics Biotech
―
Satellos Bioscience
―
Fennec Pharmaceuticals
―
Medicenna Therapeutics Corp
―
Eupraxia Pharmaceuticals
―